Katrin Bottcher

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.

Multicenter study of bleeding and thromboembolic events with durvalumab tremelimumab vs. atezolizumab and bevacizumab in advanced HCC.

Journal: JHEP reports : innovation in hepatology

Published: September 24, 2025

Peri-weaning, diet-induced activation of an IFNγ-mediated regulatory circuit promotes cDC1 maturation and CD8+ T cell differentiation.

Peri-weaning, diet-induced activation of an IFNγ-mediated regulatory circuit promotes cDC1 maturation and CD8+ T cell differentiation.

Journal: Nature communications

Published: September 10, 2025

Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD.

Polyunsaturated fatty acid-induced metabolic exhaustion and ferroptosis impair the anti-tumour function of MAIT cells in MASLD.

Journal: Journal of hepatology

Published: September 30, 2024

Microbiota metabolized Bile Acids accelerate Gastroesophageal Adenocarcinoma via FXR inhibition.

Microbiota metabolized Bile Acids accelerate Gastroesophageal Adenocarcinoma via FXR inhibition.

Journal: bioRxiv : the preprint server for biology

Published: June 25, 2024

Loss of FXR or Bile Acid-dependent Inhibition Accelerate Carcinogenesis of Gastroesophageal Adenocarcinoma.

Loss of FXR or Bile Acid-dependent Inhibition Accelerate Carcinogenesis of Gastroesophageal Adenocarcinoma.

Journal: Cellular and molecular gastroenterology and hepatology

Published: June 17, 2024

Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity.

Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity.

Journal: JHEP reports : innovation in hepatology

Published: May 12, 2024

Decreased overall survival in patients with hepatocellular carcinoma during the COVID-19 pandemic.

Decreased overall survival in patients with hepatocellular carcinoma during the COVID-19 pandemic.

Journal: Translational gastroenterology and hepatology

Published: April 24, 2024

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.

Journal: JHEP reports : innovation in hepatology

Published: April 15, 2024

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.

Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.

Journal: JHEP reports : innovation in hepatology

Published: October 04, 2023

Worst-Case X-ray Photon Energies in Ultrashort Pulse Laser Processing.

Worst-Case X-ray Photon Energies in Ultrashort Pulse Laser Processing.

Journal: Materials (Basel, Switzerland)

Published: November 11, 2022

Cell Cycle-Mediated Regulation of Secondary Ig Diversification.

Cell Cycle-Mediated Regulation of Secondary Ig Diversification.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: September 08, 2021

Context-dependent regulation of immunoglobulin mutagenesis by p53.

Context-dependent regulation of immunoglobulin mutagenesis by p53.

Journal: Molecular immunology

Published: April 27, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026